Tezpur University Researchers Uncover Blood Markers for Early Gallbladder Cancer Detection

Researchers at Tezpur University have made a significant breakthrough in the early detection of gallbladder cancer, identifying specific blood markers that differentiate cases with and without gallstones. This finding could enhance diagnostic protocols for a cancer known for its aggressive nature and often late-stage diagnosis. The study, led by Assistant Professor Dr Pankaj Barah and research scholar Dr Cinmoyee Baruah, was published in the Journal of Proteome Research of the American Chemical Society on January 10, 2024.

Gallbladder cancer ranks among the most lethal gastrointestinal cancers, particularly in Northeast India, where it is the third most common cancer. The disease is notorious for its silent progression, with many patients diagnosed at advanced stages when treatment options are severely limited. While gallstones are a known risk factor, a considerable number of patients diagnosed with gallbladder cancer do not have any history of gallstones, highlighting the need for effective early detection strategies.

The researchers conducted a pioneering pilot study involving blood samples from three distinct groups: patients with gallbladder cancer who do not have gallstones, patients with gallbladder cancer associated with gallstones, and individuals with gallstones but no cancer. The study utilized advanced metabolomics techniques, enabling the detection of hundreds of altered metabolites. Specifically, 180 metabolites were identified in cases without gallstones, while 225 metabolites were found in cases with gallstones. This comprehensive analysis led to the identification of distinct biomarker panels with high diagnostic accuracy for each group, many of which involve bile acids and amino acid derivatives linked to tumor progression.

Collaboration Drives Innovation

The research was the product of an interdisciplinary collaboration that included surgeons, pathologists, pharmaceutical scientists, molecular biologists, and computational scientists. Clinical insights were provided by institutions such as Assam Medical College and Hospital in Dibrugarh, Dr B Borooah Cancer Institute in Guwahati, and Swagat Super-Speciality Hospital. Analytical and computational support came from the University of Illinois, Urbana–Champaign, in the United States, and the CSIR–Indian Institute of Toxicology Research in Lucknow.

Highlighting the translational relevance of these findings, Dr Gayatri Gogoi, a pathologist at Assam Medical College, remarked, “By linking tissue pathology with blood metabolomics, this research bridges the gap between laboratory discoveries and clinical diagnosis.”

From a clinical perspective, Dr Subhash Khanna, a renowned gastrointestinal surgeon based in Guwahati, described the findings as a significant advancement. “The identification of blood-based metabolic markers provides a practical pathway towards early diagnosis and informed clinical decision-making,” he said.

Next Steps for Clinical Application

While the findings are promising, the researchers emphasize the need for larger, multi-centre studies to validate their results before any clinical application. Nevertheless, they believe their work lays a strong scientific foundation for developing non-invasive screening tools, particularly relevant for high-risk regions like Northeast India, where the burden of gallbladder cancer is projected to increase.

These developments in blood-based diagnostics represent a hopeful step towards improving outcomes for patients diagnosed with this challenging cancer. The potential for simple blood tests could revolutionize the early detection landscape, offering a much-needed solution for a disease that often goes undetected until it is too late.